The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia

Vaccine

Volumn 29, Issue 48, 2011, Pages 9112-9122

  Smith, Megan A ^a   Lew, Jie Bin ^a   Walker, Robert J ^a   Brotherton, Julia M L ^b   Nickson, Carolyn ^a,c   Canfell, Karen ^a,d  

^a CANCER RESEARCH DIVISION   (Australia)

^b VICTORIAN CYTOLOGY SERVICE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Australia; Cancer; Human papillomavirus (HPV); Males; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANUS CANCER; ARTICLE; AUSTRALIA; CANCER IMMUNIZATION; CANCER INCIDENCE; CHILD; DRUG EFFICACY; FEMALE; FEMALE GENITAL TRACT INFECTION; HEAD AND NECK CANCER; HEALTH PROGRAM; HETEROSEXUALITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALE FERTILITY; MALE GENITAL TRACT INFECTION; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; VACCINATION; VIRUS TRANSMISSION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MASS VACCINATION; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; YOUNG ADULT;

EID: 82455175222     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.091     Document Type: Article

References (64)

1. Pharmaceutical Benefits Advisory Committee (PBAC). Public summary document for Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) recombinant vaccine, injection, 0.5mL, Gardasil® [cited 11 October 2010]. Available from http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-gardasil-nov06.
2. Kulasingam S., Connelly L., Conway E., Hocking J.S., Myers E., Regan D.G., et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007, 4(3):165-175.
3. Advisory Committee on Prescription Medicines. ACPM 270th meeting recommendations [cited 29 November 2010]. Available from http://www.tga.gov.au/committee/acpm/acpm0270.htm.
4. International Agency for Research on Cancer IARC Monographs on the evaluation of carcinogenic risk to humans: human papillomaviruses 2007, vol. 90. IARC, Lyon, France.
5. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. New Engl J Med 2011, 364(5):401-411.
6. Grulich A.E., Jin F., Conway E.L., Stein A.N., Hocking J. Cancers attributable to human papillomavirus infection. Sex Health 2010, 7(3):244-252.
7. Brotherton J., Deeks S., Campbell-Lloyd S., Misrachi A., Passaris I., Peterson K., et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008, 32(4):457-461.
8. Gertig D.M., Brotherton J.M.L. Why an HPV vaccine register? Coverage estimates from and role of the National HPV Vaccination Program Register, Australia. 26th International Papillomavirus Conference 2010.
9. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-Principle: efficacy of fewer than 3-doses of a bivalent HPV 16/18 vaccine against incident persistent HPV infection in Guanacaste, Costa Rica. 26th International Papillomavirus Conference 2010.
10. Smith M.A., Canfell K., Brotherton J.M., Lew J.B., Barnabas R.V. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008, 123(8):1854-1863.
11. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med/Public Libr Sci 2006, 3(5):e138.
12. Garland S., Brotherton J., Stevens M.P., Condon J., McIntyre P.B., Smith D., et al. WHINURS HPV genotype prevalence in Australian women pre-vaccination: what differences might there be for Indigenous women?. 26th International Papillomavirus Conference 2010.
13. IARC Monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses 2007, vol. 90. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, IARC, Lyon. 90th ed.
14. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3). S3-11-S3/25.
15. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475.
16. Herrero R., Castellsague X., Pawlita M., Lissowska J., Kee F., Balaram P., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003, 95(23):1772-1783.
17. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113(10 Suppl.):3036-3046.
18. D'Souza G., Kreimer A.R., Viscidi R., Pawlita M., Fakhry C., Koch W.M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007, 356(19):1944-1956.
19. Hong A.M., Grulich A.E., Jones D., Lee C.S., Garland S.M., Dobbins T.A., et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010, 28(19):3269-3272.
20. Hoots B.E., Palefsky J.M., Pimenta J.M., Smith J.S. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009, 124(10):2375-2383.
21. De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124(7):1626-1636.
22. Daling J.R., Madeleine M.M., Johnson L.G., Schwartz S.M., Shera K.A., Wurscher M.A., et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004, 101(2):270-280.
23. Backes D.M., Kurman R.J., Pimenta J.M., Smith J.S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009, 20(4):449-457.
24. Krustrup D., Jensen H.L., Van Den Brule A.J., Frisch M. Histological characteristics of human papilloma-virus-positive and -negative invasive and in situ squamous cell tumours of the penis. Int J Exp Pathol 2009, 90(2):182-189.
25. Miralles-Guri C., Bruni L., Cubilla A.L., Castellsague X., Bosch F.X., De S.S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62(10):870-878.
26. Heideman D.A., Waterboer T., Pawlita M., is-van D.P., Nindl I., Leijte J.A., et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007, 25(29):4550-4556.
27. Fakhry C., Westra W.H., Li S., Cmelak A., Ridge J.A., Pinto H., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008, 100(4):261-269.
28. Paz I.B., Cook N., Odom-Maryon T., Xie Y., Wilczynski S.P. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 1997, 79(3):595-604.
29. Australian Institute of Health and Welfare. Cancer data online [cited 13 December 2010]. Available from http://www.aihw.gov.au/cancer/data/datacubes/index.cfm.
30. Australian Bureau of Statistics (ABS). Australian demographic statistics, June Quarter 2001. December 2001. Report No.: 3101.0.
31. Fairley C.K., Hocking J.S., Gurrin L.C., Chen M.Y., Donovan B., Bradshaw C. Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sex Transm Infect 2009, 85(7):499-502.
32. Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11(1):39-44.
33. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10(11):1915-1923.
34. Kim J.J., Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.
35. Kim J.J., Andres-Beck B., Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97(9):1322-1328.
36. Choi Y.H., Jit M., Gay N., Cox A., Garnett G.P., Edmunds W.J. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010, 28(24):4091-4102.
37. Elbasha E.H., Dasbach E.J. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28(42):6858-6867.
38. Brisson M., van de Velde N., Boily M.C. Modeling the incremental impact of vaccinating boys against HPV. 26th International Papillomavirus Conference 2010.
39. Brisson M., van de Velde N., Boily M.C. Impact of disparities in HPV vaccine coverage on population-level effectiveness. 26th International Papillomavirus Conference 2010.
40. Newall A.T., Brotherton J.M., Quinn H.E., McIntyre P.B., Backhouse J., Gilbert L., et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008, 46(11):1647-1655.
41. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181(6):1911-1919.
42. Carter J.J., Wipf G.C., Hagensee M.E., McKnight B., Habel L.A., Lee S.K., et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995, 172(1):11-18.
43. Palefsky J. Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference 2010.
44. Ramqvist T., Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis [serial on the Internet] 2010, 16(11):1671-1677.
45. Smith A.M., Rissel C.E., Richters J., Grulich A.E., de Visser R.O. Sex in Australia: sexual identity, sexual attraction and sexual experience among a representative sample of adults. Aust N Z J Public Health 2003, 27(2):138-145.
46. Daling J.R., Weiss N.S., Hislop T.G., Maden C., Coates R.J., Sherman K.J., et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987, 317(16):973-977.
47. Kim J.J. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010, 10(12):845-852.
48. National Centre in HIV Epidemiology and Clinical Research HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010 2010, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW.
49. Grulich A.E., de Visser R.O., Smith A.M., Rissel C.E., Richters J. Sex in Australia: sexually transmissible infection and blood-borne virus history in a representative sample of adults. Aust N Z J Public Health 2003, 27(2):234-241.
50. Simatherai D., Bradshaw C.S., Fairley C.K., Bush M., Heley S., Chen M.Y. What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 2009, 85(2):148-149.
51. Wikstrom A., Popescu C., Forslund O. Asymptomatic penile HPV infection: a prospective study. Int J STD AIDS 2000, 11(2):80-84.
52. Giuliano A.R., Lu B., Nielson C.M., Flores R., Papenfuss M.R., Lee J.H., et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008, 198(6):827-835.
53. Kjaer S.K., Munk C., Winther J.F., Jorgensen H.O., Meijer C.J., Van Den Brule A.J. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005, 14(6):1528-1533.
54. Lajous M., Mueller N., Cruz-Valdez A., Aguilar L.V., Franceschi S., Hernandez-Avila M., et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005, 14(7):1710-1716.
55. Plummer M., Schiffman M., Castle P.E., Maucort-Boulch D., Wheeler C.M. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007, 195(11):1582-1589.
56. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007, 96(9):1419-1424.
57. Rodriguez A.C., Schiffman M., Herrero R., Wacholder S., Hildesheim A., Castle P.E., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100(7):513-517.
58. Molano M., Van den Brule A., Plummer M., Weiderpass E., Posso H., Arslan A., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158(5):486-494.
59. Koshiol J.E., Schroeder J.C., Jamieson D.J., Marshall S.W., Duerr A., Heilig C.M., et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006, 119(7):1623-1629.
60. Brown D.R., Shew M.L., Qadadri B., Neptune N., Vargas M., Tu W., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005, 191(2):182-192.
61. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(5):2135-2145.
62. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26(3):201-209.
63. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5years of follow-up. Br J Cancer 2006, 95(11):1459-1466.
64. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4years. Lancet 2009, 374(9706):1975-1985.